
XAIR Stock Forecast & Price Target
XAIR Analyst Ratings
Bulls say
Beyond Air is a commercial-stage medical device and biopharmaceutical company that has developed the LungFit platform, which uses nitric oxide generated from ambient air to treat various diseases, including neurological and neuro-oncology indications, viral pneumonia, and cancer. Their recent encouraging data from the Beyond Cancer segment and a proposed transaction to monetize the NeuroNOS platform could potentially bring significant value to the company and its shareholders in the future. Additionally, the consistent revenue growth shown in the US LungFit market also indicates potential for success and growth in the future.
Bears say
Beyond Air is facing a challenging market as they attempt to commercialize their LungFit platform and diversify their revenue streams. Despite a recent leadership change and promising revenue growth, the company's over-reliance on LungFit and a failed attempt to sell their NeuroNOs subsidiary highlights potential risks and weaknesses in their strategy. While Beyond Air still has potential for growth, investors may want to approach with caution until the company can demonstrate proven success in diversifying their business and improving go-to-market execution.
This aggregate rating is based on analysts' research of Beyond Air Inc and is not a guaranteed prediction by Public.com or investment advice.
XAIR Analyst Forecast & Price Prediction
Start investing in XAIR
Order type
Buy in
Order amount
Est. shares
0 shares